Paul is Head of the Clinical Psychedelic Lab, and Senior Research Fellow in the Department of Psychiatry at Monash University. He has played a central role in establishing the field of clinical psychedelic research in Australia, and is the principal investigator on a program of psychedelic trials. He leads the country’s largest and most experienced group of psychedelic researchers and clinicians, is involved in numerous psychedelic studies across the country, and collaborates with many international experts and organisations in the field. He has led several world-first studies, including the first trial to use psilocybin in the treatment of a primary anxiety condition, the first study testing the utility of psilocybin as a therapist training tool, and the first trial testing a psychedelic-augmented virtual-reality treatment. In Australia, he established the first psychedelic lab, coordinated the first applied psychedelic therapist training program, and obtained the first industry funding for psychedelic research. Together with clinical and industry colleagues, he co-founded Australia’s first purpose-built psychedelic-assisted therapy clinic. He is regularly invited to speak on psychedelic science for academia, medical peak bodies, industry, and government. His work is focused on investigating novel applications for psychedelic therapies, translating evidence into best clinical practice, exploring under-examined risks, delivering next-generation therapist training, and improving access and affordability.